HCWB
HCW Biologics Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.87
+0.00%Sep 2, 2026, 13:00 UTC
HCW Biologics announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for claims directed to use of HCW9302 to treat alopecia areata.
Source:Aug 14, 2026, 19:15 UTC
HCW Biologics reported financial results for the three and six months ended June 30, 2026.
Source:Jul 29, 2026, 13:06 UTC
HCW Biologics Inc. priced a $1.6 million private placement offering of units consisting of common stock or pre-funded warrants and common stock purchase warrants to a group of investors including officers, directors and an existing stockholder.
Source:Jun 30, 2026, 00:00 UTC
HCW Biologics Inc. regained compliance with NASDAQ's minimum bid price rule after effecting a one-for-six reverse stock split on June 30, 2026.
Jun 26, 2026, 12:55 UTC
HCW Biologics announced a 1-for-6 reverse stock split effective June 30, 2026, to maintain Nasdaq compliance.
Source:Jun 16, 2026, 11:00 UTC
HCW Biologics announced positive preliminary human data readout for its Phase 1 clinical trial of HCW9302 in alopecia areata.
Source:May 21, 2026, 00:00 UTC
HCW Biologics Inc. signed a definitive agreement for a $4.0 million at-the-market private placement offering of units consisting of common stock (or pre-funded warrants) and common warrants, with closing expected on or about May 26, 2026.